Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kay Tetzlaff

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
BMJ Open|March 31, 2021
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flareSiew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, et al.
The European Respiratory Journal|July 2, 2021
Effects of nintedanib by inclusion criteria for progression of interstitial lung diseaseToby M Maher, Kevin K Brown, Michael Kreuter, et al.
The European Respiratory Journal|January 10, 2015
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)Roland Buhl, François Maltais, Roger Abrahams, et al.
The European Respiratory Journal|June 2, 2015
Author correction. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)Roland Buhl, François Maltais, Roger Abrahams, et al.
The New England Journal of Medicine|December 22, 2021
Trial of Spesolimab for Generalized Pustular PsoriasisHervé Bachelez, Siew-Eng Choon, Slaheddine Marrakchi, et al.
The New England Journal of Medicine|October 1, 2019
Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|February 17, 2015
Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPDDavid M Mannino, Ruth Tal-Singer, David A Lomas, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|September 6, 2022
Endurance Time During Constant Work Rate Cycle Ergometry in COPD: Development of an Integrated Database From Interventional StudiesRichard Casaburi, Debora Merrill, Thomas Dolmage, et al.
ERJ Open Research|June 24, 2021
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung diseaseRobin Deterding, Matthias Griese, Gail Deutsch, et al.
Annals of the American Thoracic Society|December 18, 2023
Validation of Constant Work Rate Cycling Endurance Time for Use in Chronic Obstructive Pulmonary Disease Clinical TrialsRichard Casaburi, Debora Merrill, Nancy Kline Leidy, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
BMJ Open|March 31, 2021
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flareSiew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, et al.
The European Respiratory Journal|July 2, 2021
Effects of nintedanib by inclusion criteria for progression of interstitial lung diseaseToby M Maher, Kevin K Brown, Michael Kreuter, et al.
The European Respiratory Journal|January 10, 2015
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)Roland Buhl, François Maltais, Roger Abrahams, et al.
The European Respiratory Journal|June 2, 2015
Author correction. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)Roland Buhl, François Maltais, Roger Abrahams, et al.
The New England Journal of Medicine|December 22, 2021
Trial of Spesolimab for Generalized Pustular PsoriasisHervé Bachelez, Siew-Eng Choon, Slaheddine Marrakchi, et al.
The New England Journal of Medicine|October 1, 2019
Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|February 17, 2015
Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPDDavid M Mannino, Ruth Tal-Singer, David A Lomas, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|September 6, 2022
Endurance Time During Constant Work Rate Cycle Ergometry in COPD: Development of an Integrated Database From Interventional StudiesRichard Casaburi, Debora Merrill, Thomas Dolmage, et al.
ERJ Open Research|June 24, 2021
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung diseaseRobin Deterding, Matthias Griese, Gail Deutsch, et al.
Annals of the American Thoracic Society|December 18, 2023
Validation of Constant Work Rate Cycling Endurance Time for Use in Chronic Obstructive Pulmonary Disease Clinical TrialsRichard Casaburi, Debora Merrill, Nancy Kline Leidy, et al.
Pageof 7